Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
iRay Technology Company Limited (688301.SS)
CNY98.48
-1.90 (-1.89%)
CN SHH Healthcare Medical - Instruments & Supplies
Address
Building 45 201206
Shanghai, CN
Shanghai, CN
CEO
Tieer Gu
Website
iraygroup.com
IPO
2020-09-18
ISIN CNE1000042V8
Description
iRay Technology Company Limited specializes in the development, manufacturing, and global distribution of sophisticated flat panel X-ray detectors. These critical imaging components are utilized across a broad spectrum of applications, including medical diagnostics, dental imaging, oncology treatment planning, veterinary care, security screening, and industrial inspection, serving markets both within China and internationally. The company's diverse product portfolio features solutions such as wireless and tethered radiography panels, mammography detectors, dynamic/real-time imaging systems, and linear detector arrays, all supported by essential accompanying software. Founded in 2011, iRay Technology is headquartered in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY98.48
-1.90 (-1.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.77
Float Shares
146.10M
Free Float %
69.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.83% | +12.05% | +76.28% | +66.50% | +94.57% | +99.78% | +115.40% | +37.39% | +95.72% | +246.25% | +246.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
98.48
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.87
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+22.9% ★ Q1'26: +42.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+38.0% ★ Q1'26: +15.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+46.3% ★ Q1'26: -67.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+26.4% ★ Q1'26: +23.6% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.7% ★ Q1'26: +7.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-3.7% ★ Q1'26: +7.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×5.26× Q1'26: 7.42× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
784.08M
est: 850.30M (-7.8%)
|
1.19B
est: 1.18B (+1.0%)
|
1.55B
est: 1.62B (-4.6%)
|
1.86B
est: 1.93B (-3.6%)
|
1.83B
est: 1.95B (-6.0%)
|
2.25B
est: 2.21B (+1.7%)
|
3.45B
3.16B – 3.54B
+55.7% YoY
|
4.43B
3.41B – 4.98B
+28.5% YoY
|
5.41B
5.37B – 5.44B
+22.1% YoY
|
| EBITDA |
282.04M
est: 281.20M (+0.3%)
|
586.33M
est: 388.59M (+50.9%)
|
750.21M
est: 537.17M (+39.7%)
|
742.41M
est: 790.60M (-6.1%)
|
584.85M
est: 796.64M (-26.6%)
|
786.64M
est: 905.38M (-13.1%)
|
1.41B
1.29B – 1.45B
+55.7% YoY
|
1.81B
1.40B – 2.04B
+28.5% YoY
|
2.21B
2.20B – 2.22B
+22.1% YoY
|
| EBIT |
258.03M
est: 262.13M (-1.6%)
|
562.20M
est: 362.24M (+55.2%)
|
721.51M
est: 500.76M (+44.1%)
|
711.57M
est: 726.12M (-2.0%)
|
537.10M
est: 731.66M (-26.6%)
|
594.54M
est: 831.53M (-28.5%)
|
1.29B
1.19B – 1.33B
+55.7% YoY
|
1.66B
1.28B – 1.87B
+28.5% YoY
|
2.03B
2.02B – 2.04B
+22.1% YoY
|
| Net Income |
222.25M
est: 158.69M (+40.0%)
|
484.04M
est: 317.30M (+52.6%)
|
641.30M
est: 478.83M (+33.9%)
|
607.50M
est: 784.68M (-22.6%)
|
465.18M
est: 492.30M (-5.5%)
|
650.01M
est: 685.66M (-5.2%)
|
838.99M
752.39M – 880.41M
+22.4% YoY
|
1.01B
876.00M – 1.09B
+20.5% YoY
|
1.23B
1.13B – 1.28B
+22.0% YoY
|
| SGA |
66.14M
est: 84.81M (-22.0%)
|
113.30M
est: 117.20M (-3.3%)
|
174.81M
est: 162.01M (+7.9%)
|
177.97M
est: 169.40M (+5.1%)
|
202.52M
est: 170.69M (+18.6%)
|
53.79M
est: 193.99M (-72.3%)
|
301.96M
277.16M – 310.68M
+55.7% YoY
|
388.02M
299.15M – 436.51M
+28.5% YoY
|
473.75M
470.76M – 476.74M
+22.1% YoY
|
| EPS |
1.37
est: 1.07 (+28.3%)
|
2.43
est: 2.13 (+13.8%)
|
3.22
est: 3.22 (-0.1%)
|
3.04
est: 4.13 (-26.5%)
|
2.33
est: 2.90 (-19.5%)
|
3.20
est: 3.28 (-2.4%)
|
3.93
3.75 – 4.39
+19.9% YoY
|
4.92
4.37 – 5.46
+25.0% YoY
|
5.91
5.62 – 6.39
+20.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-211.87M
OE per share TTM
-0.88
Owner's Yield
-0.50%
Maintenance CapEx ratio
198.47%
Maint CapEx / Avg PPE
88.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 28 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.21% | 75.9K | 0.65% |
| 2 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 37.8K | 0.55% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 177.3K | 0.19% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 31.6K | 0.44% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 115.0K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 51.0K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.68M | 0.06% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 245.4K | 0.39% |
| 9 | JPMorgan BetaBuilders Emerging Markets Equity ETF BBEM | 0.00% | 21.3K | 0.15% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 239.7K | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
357.9K
Shares Outstanding
211.45M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chengbin Qiu | Chief Technology Officer, Deputy GM, & Director | — | male |
| Dong Zhao | Deputy General Manager | — | male |
| Guo Hua Zhang | Deputy General Manager | — | male |
| Min Qiu | Secretary | — | female |
| Tieer Gu | Chairman & GM | — | male |
| Xiaoyu Dong | Deputy General Manager | — | male |
| Yan Jiang | Chief Financial Officer | — | female |
| Yancheng Lin | Core Technical Staff | — | male |
| Yimin Huang | Deputy GM & Core Technical Staff | — | male |
| Yuhan Tong | Accounting Supervisor | — | — |
| Zhiqiang Fang | Deputy GM & Core Technician | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688301.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
